Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Prostate cancer poses a significant public health challenge in the Middle East, with advanced-stage diagnoses and high mortality rates. However, projections regarding its future incidence are limited. The aims of this study were to estimate prostate cancer incidence in the region through 2050, to evaluate socioeconomic factors contributing to regional disparities, and to provide insights to inform future health care policies and resource allocation.

Methods: Data from the Global Cancer Observatory were analyzed for Middle Eastern countries, with Europe and North America included for comparison. The percentage change in incidence between 2022 and 2050 was compared across regions using the Mann-Whitney test. Additional subgroup analyses based on income level and Human Development Index were performed using Kruskal-Wallis test. Spearman rank correlation was used to explore the association between incidence trends and socioeconomic indicators.

Results: In 2022, Middle Eastern countries reported 50,944 patients with newly diagnosed prostate cancer, accounting for 3.47% of global incidence. The projected increase in prostate cancer incidence by 2050 was significantly higher in the Middle East compared with Europe and North America (mean rank, 12.50 1.50; = .009). Higher income countries exhibited a greater percentage increase ( = .033), and the income level correlated positively with incidence trends ( = 59.6%; = .006). Countries with increasing incidence rates had a markedly higher percentage change than those expected to decline ( = .031).

Conclusion: Prostate cancer incidence in the Middle East is expected to rise substantially by 2050, with socioeconomic disparities influencing disease trends. These findings highlight the urgent need for targeted awareness campaigns, improved screening strategies, enhanced oncology infrastructure, and strengthened cancer registries to mitigate the projected burden and improve outcomes in the region.

Download full-text PDF

Source
http://dx.doi.org/10.1200/GO-25-00098DOI Listing

Publication Analysis

Top Keywords

prostate cancer
24
cancer incidence
16
middle east
16
incidence
10
cancer
8
incidence middle
8
2050 socioeconomic
8
socioeconomic disparities
8
middle eastern
8
eastern countries
8

Similar Publications

This review aims to describe the role of poly-ADP-ribose polymerase inhibitors (PARPi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC), an aggressive and lethal form of the disease. The introduction of PARPi has led to improved prognosis, particularly in patients with at least one somatic or germline mutation in DNA damage repair genes such as BRCA1 or BRCA2. Several recent studies have shown that PARPi, used alone or in combination with abiraterone or enzalutamide, improve progression-free survival and overall survival in patients with mCRPC.

View Article and Find Full Text PDF

This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience.

View Article and Find Full Text PDF

Purpose: Screening and diagnosing ISUP ≥ 2 prostate cancer is challenging. This study aimed to determine whether canine detection could be beneficial addition to the ISUP ≥ 2 prostate cancer diagnostic protocol by creating a decision-making algorithm for men with suspected prostate cancer.

Methods: We conducted a prospective study at two urology institutions and a French veterinary school, including men with a suspicion of prostate cancer from November to April 2023, which were divided into two groups according to their prostate biopsy results.

View Article and Find Full Text PDF

Background: The optimal management of synchronous rectal cancer (RC) and prostate cancer (PC) remains unclear. This systematic review evaluates treatment strategies and reports postoperative, oncological, and quality-of-life outcomes in patients treated with curative intent.

Methods: Following PRISMA guidelines, this systematic review was registered in PROSPERO (CRD42024598049).

View Article and Find Full Text PDF

Neural activity is increasingly recognized as a crucial regulator of cancer growth. In the brain, neuronal activity robustly influences glioma growth through paracrine mechanisms and by electrochemical integration of malignant cells into neural circuitry via neuron-to-glioma synapses. Outside of the central nervous system, innervation of tumours such as prostate, head and neck, breast, pancreatic, and gastrointestinal cancers by peripheral nerves similarly regulates cancer progression.

View Article and Find Full Text PDF